Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

Core Insights - Intellia Therapeutics is a gene editing company focused on in vivo applications with a strong emphasis on late-stage programs [5] Group 1: Company Overview - The company has two main assets and is conducting three Phase III studies in various indications [5] - Intellia has made significant operational progress and restructured its financial plan earlier in the year [5] - The company is optimistic about upcoming catalysts over the next 12 to 18 months [5]